This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Agilent Technologies, Inc., Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC. Active years: 2020-2026.
Company Filing History:
3 out of 4,730 
2 out of 2,405 
1 out of 67 Years Active: 2020-2026
Title: The Innovations of David Stanforth
Introduction
David Stanforth is an accomplished inventor based in Carpinteria, CA (US). He has made significant contributions to the field of medical technology, particularly in the area of cancer treatment. With a total of 3 patents to his name, Stanforth's work focuses on improving therapeutic methods for patients with malignancies.
Latest Patents
Stanforth's latest patents include innovative scoring methods for determining the eligibility of subjects with malignancies for treatment with anti-PD therapeutic agents. These methods utilize a Combined Positive Score (CPS) derived from tumor tissue samples. The patents also encompass compositions and kits designed to facilitate the application of these methods, showcasing his commitment to advancing cancer treatment.
Career Highlights
Throughout his career, David Stanforth has worked with notable companies such as Agilent Technologies, Inc. and Merck Sharp & Dohme Corp. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to the advancement of medical technologies.
Collaborations
Stanforth has collaborated with talented individuals in his field, including Greg Angelides and Nancy Zhang. These partnerships have likely enriched his work and fostered a collaborative environment for innovation.
Conclusion
David Stanforth's contributions to the field of medical technology through his patents and collaborations highlight his dedication to improving cancer treatment. His innovative approaches continue to pave the way for advancements in therapeutic methods.